Colgate-Palmolive 배당 및 자사주 매입
배당 기준 점검 5/6
Colgate-Palmolive 수익으로 충분히 충당되는 현재 수익률 2.34% 보유한 배당금 지급 회사입니다.
핵심 정보
2.3%
배당 수익률
1.4%
자사주 매입 수익률
| 총 주주 수익률 | 3.8% |
| 미래 배당 수익률 | 2.5% |
| 배당 성장률 | 3.1% |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | 80% |
최근 배당 및 자사주 매입 업데이트
Recent updates
Seeking Alpha • May 10
Colgate-Palmolive: Too Expensive For A Defensive Firm
Summary Colgate-Palmolive delivered 8% sales growth in Q1 2026, but EPS declined 6%, warranting a conservative hold rating. I see organic growth of just 2.9%, with North America sales falling due to increased toothpaste competition and margin compression. FX tailwinds drove significant growth in Latin America, EMEA, and APAC, raising concerns about sustainability if currency trends reverse. Persistent low U.S. consumer confidence and elevated input costs, including a $300M Middle East impact, create near-term headwinds for CL. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 09
CL: 2030 Plan Execution And Margins Will Shape 2026 Setup
Analysts have trimmed the Colgate-Palmolive fair value estimate by about $0.58 to $96.68, reflecting slightly softer revenue growth assumptions, a modestly lower future P/E, and mixed recent research that includes both reduced price targets and an upgrade tied to confidence in the 2030 plan and ongoing margin resilience. Analyst Commentary Recent Street research on Colgate-Palmolive shows a mix of optimism around the long-term plan and caution around nearer term cost and valuation risks.내러티브 업데이트 • Mar 25
CL: 2030 Plan And Emerging Markets Execution Will Shape 2026 Setup
Colgate-Palmolive's fair value estimate edges up to $97.26 from $97.21 as analysts lift price targets toward the $100 to $105 range, citing stronger confidence in the 2030 plan, product innovation, and emerging markets execution. Analyst Commentary Recent Street research on Colgate-Palmolive clusters around higher price targets and upgraded ratings, with the fair value conversation increasingly framed around the 2030 plan, execution in emerging markets, and portfolio moves such as the exit from private label pet food.내러티브 업데이트 • Mar 10
CL: 2030 Plan And Emerging Markets Support Measured 2026 Execution Setup
Analysts have nudged their price expectations for Colgate-Palmolive higher, with the updated fair value estimate moving from about $96.68 to roughly $97.21. They cite growing confidence in the company’s 2030 plan, product innovation efforts and emerging markets exposure, as reflected in a series of recent price target increases across major firms.내러티브 업데이트 • Feb 24
CL: 2030 Plan And Emerging Markets Will Drive Balanced 2026 Setup
Analysts have raised their implied price target for Colgate-Palmolive by about $8 to reflect higher conviction in the company’s 2030 plan, product innovation pipeline and emerging market exposure, as well as refreshed views on sector valuations. Analyst Commentary Recent research has centered on how Colgate-Palmolive’s 2030 plan, product pipeline and emerging market footprint feed into both growth potential and current valuation.분석 기사 • Feb 06
There May Be Some Bright Spots In Colgate-Palmolive's (NYSE:CL) Earnings
Colgate-Palmolive Company's ( NYSE:CL ) recent soft profit numbers didn't appear to worry shareholders, as the stock...내러티브 업데이트 • Jan 28
CL: Emerging Markets And 2026 Setup Will Shape Balanced Risk Reward
Analysts have nudged their price targets for Colgate-Palmolive higher, reflected in a modest fair value move from about $87.47 to $88.89. They are factoring in slightly stronger revenue growth assumptions, a marginally higher future P/E and recent rating and target changes across firms such as Barclays, JPMorgan, UBS, Wells Fargo, Piper Sandler and TD Cowen.내러티브 업데이트 • Jan 10
CL: Emerging Markets And 2026 Setup Support Balanced Outlook After Recent Softness
Our updated analyst price target for Colgate-Palmolive edges up to about US$87.47 from roughly US$87.21, as analysts balance slightly softer modeled revenue growth with modestly higher profit margin and future P/E assumptions. This view is supported by recent research that pairs cautious consumer staples outlooks with a more positive stance on the company’s emerging markets exposure and potential 2026 acceleration.내러티브 업데이트 • Dec 15
CL: Emerging Market Strength Will Support Gradual Recovery As Q3 Softness Fades
Analysts have trimmed their price target on Colgate-Palmolive to $87 from the low-to-mid $90s, reflecting near term softness in Q3 results and muted personal care growth, even as they expect organic sales momentum to gradually improve. Analyst Commentary Analysts remain divided on Colgate-Palmolive, with recent target cuts reflecting near term execution risk, while longer term growth and margin recovery expectations stay largely intact.내러티브 업데이트 • Nov 30
CL: Gradual Recovery Expected As Temporary Headwinds Ease In Personal Care Markets
Narrative Update on Colgate-Palmolive Colgate-Palmolive's analyst price target has been modestly reduced by $0.05 to $87.21. Analysts cite near-term growth challenges and muted sector outlooks following a soft Q3, but expect gradual improvement as temporary pressures ease.내러티브 업데이트 • Nov 16
CL: Organic Sales Momentum Will Rebound As Near-Term Headwinds Ease
Colgate-Palmolive's analyst consensus price target was revised downward from approximately $88.84 to $87.26. Analysts cite a soft third quarter, moderated growth expectations, and ongoing category headwinds as key factors behind the adjustment.내러티브 업데이트 • Nov 02
CL: Future Cost Optimization Will Drive Competitive Advantage Amid Category Headwinds
Colgate-Palmolive’s fair value estimate has been reduced from $90.74 to $88.84 per share. Analysts cite persistent category headwinds and a moderated sales outlook as factors behind lower price targets across the sector.내러티브 업데이트 • Oct 18
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst fair value price target has decreased from $93.11 to $90.74. Analysts cite lowered sales guidance, persistent category headwinds, and muted growth outlooks as key factors behind their revised estimates.내러티브 업데이트 • Oct 03
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst price target has been revised downward by approximately $2 to $93. Analysts cite ongoing category headwinds and decelerating growth in the personal care sector as reasons for this adjustment.분석 기사 • Sep 30
There's Reason For Concern Over Colgate-Palmolive Company's (NYSE:CL) Price
Colgate-Palmolive Company's ( NYSE:CL ) price-to-earnings (or "P/E") ratio of 22.3x might make it look like a sell...분석 기사 • Aug 04
Colgate-Palmolive Company (NYSE:CL) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that Colgate-Palmolive Company ( NYSE:CL ) filed its quarterly result this time last...분석 기사 • Jun 27
Colgate-Palmolive (NYSE:CL) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Jun 12
Do Colgate-Palmolive's (NYSE:CL) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Apr 22
A Historic Brand, A Fresh Approach: Inside Colgate-Palmolive's Machine
Summary Colgate-Palmolive achieved over $20 billion in revenue in 2024, driven by strong brand identity, operational discipline, and a diversified product portfolio across Oral Care, Personal Care, Home Care, and Pet Nutrition. The company maintained profitability despite inflation, with a 14.4% margin, and continued to invest in marketing and R&D, enhancing brand differentiation and price stability. Financially robust, Colgate-Palmolive showed significant revenue and margin growth, generating record free cash flow, and is well-positioned for 2025 with a "Buy" rating and a target share price of $100.08. Key risks include currency fluctuations, raw material costs, and competition, but strong daily demand for products and innovation in high-growth segments like Pet Nutrition support long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 20
Colgate-Palmolive: A Defensive Stock With Growth Potential
Summary Colgate-Palmolive is one of the leaders in the global toothpaste market. On January 31, Colgate-Palmolive released financial results that left me with mixed reactions. Demand for its products in Latin America is growing rapidly, but the strengthening of the US dollar has not allowed Colgate-Palmolive to fully reflect this in its EPS. In this article, you, Seeking Alpha readers, will learn why, according to my "ALLKA 4D Rating" model, Colgate-Palmolive is a stock with an attractive risk/reward ratio. Read the full article on Seeking AlphaSeeking Alpha • Mar 14
Is Colgate-Palmolive Quietly Building The Next Pet Food Empire?
Summary Colgate-Palmolive's premiumization strategy and pet nutrition expansion offer significant growth potential, with a price target of $115 per share, suggesting a 26% upside. Despite high valuation metrics, CL's superior profitability, high margins, and exceptional cash flow justify its premium valuation and long-term investment appeal. The company's strong pricing power, particularly in premium oral care and pet food, positions it well against inflation and competitive pressures. Risks include potential valuation compression and competition in pet nutrition, but CL's consistent cash flow and brand strength mitigate these concerns. Read the full article on Seeking AlphaSeeking Alpha • Feb 25
Colgate-Palmolive: Don't Get Your Hopes Up (Yet)
Summary After a strong first half of 2024, Colgate-Palmolive's stock continues to be an underperformer in the consumer staples sector. The stock is trading at a discount to the level implied by current margins, but there is a good reason for that. Margins are likely to come under pressure in 2025 and from a dividend point of view, CL also appears unattractive at the moment. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Colgate-Palmolive Stock: Post-Earnings Drop Isn't A Buy-The-Dip Moment
Summary Toothpaste and manual toothbrushes market leader Colgate-Palmolive Company released its fourth quarter and full-year 2024 results today. Judging by the share price reaction, and considering CL stock is down more than 20% from its all-time high, this clearly looks like a “buy the dip” moment. However, I'll explain why I don't think it's a good idea to buy CL shares, either for dividend or total return investors, and despite the company's undoubtedly solid 2024 performance. Read the full article on Seeking AlphaSeeking Alpha • Dec 17
Colgate-Palmolive: Digital Advertising Is The Base From Which To Start Again
Summary Colgate-Palmolive's (CL) revenue growth has been minimal over the past decade, with a CAGR of only 1.53%, not even keeping pace with inflation. Despite a 61-year streak of increasing dividends, CL's EPS growth has been stagnant, leading to a higher payout ratio. Increased advertising expenditures, particularly in digital, have shown higher ROI than traditional channels. CL's future growth may hinge on digital advertising and expanding into Personal and Home Care markets, but the current valuation is too high for a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Colgate-Palmolive: Approaching Buy Territory With Some Important Catalysts
Summary As expected, Colgate-Palmolive's stock has retreated from its recent highs over the past few months. Upside potential for 2025 remains limited as gross margin tailwinds are fading. Nonetheless, there are some key areas that investors should keep a close eye on over the course of next year. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Colgate-Palmolive Q3: Great Company, But Not Enough To Warrant A Position Now
Summary Colgate-Palmolive Company's Q3 earnings showed mixed results, with revenue and EPS beating estimates but North America and Latin America sales declining, leading to a 3% stock drop. The company's improved gross margins and increased advertising spend are positive signs, but the market remains concerned about regional sales declines. The Pet Nutrition segment shows strong growth potential, driven by the pet humanization trend, and could be a key revenue catalyst. Given macroeconomic uncertainties and regional performance, I rate Colgate-Palmolive stock as a hold, awaiting further developments in NA, LatAm, and Pet Nutrition segments. Read the full article on Seeking AlphaSeeking Alpha • Oct 17
Colgate-Palmolive: Very Close To A Buy Following Recent Pullback
Summary Colgate-Palmolive is a high-quality business with consistent revenue growth, stable gross profit margins, and a strong return on invested capital, making it a solid dividend stock. The company has an impressive 61-year streak of consecutive dividend growth, maintaining a healthy payout ratio of around 60%, ensuring future dividend increases. The recent pace of dividend growth is below par but in line with inflation and top-line business growth. The recent pullback has brought the share price down very close to fair value. With earnings around the corner now may be a good time to consider jumping aboard. Colgate has beaten earnings estimates during the last 5 consecutive quarters, and recent analyst revisions indicate FQ3 may follow suit. Read the full article on Seeking AlphaSeeking Alpha • Sep 30
Colgate-Palmolive: Share Price Returns Should Moderate (Rating Downgrade)
Summary Since I turned bullish on the stock, Colgate-Palmolive delivered a 36% total return in less than 10 months. For a consumer staples company the size of CL, returns will most likely moderate from here for two main reasons. As the impact of pricing initiatives fades away, investors should keep a close eye on volumes over the coming year. Read the full article on Seeking AlphaSeeking Alpha • Aug 19
Colgate-Palmolive: Stability Pillar Reached Its Fair Value
Summary Colgate-Palmolive operates globally with a strong presence in over 200 countries, deriving two-thirds of revenue from non-US markets. The Company is a member of the Dividend Kings group, offering reliable dividend income, which grew consecutively for 60 years. Strong organic growth in primary segments (partially offset by FX fluctuations), with profitable operations and solid margins ensuring shareholder rewards. Upon stock price increases during the last couple of quarters, CL's multiple reached its fair level. Therefore, I remain a happy holder, but I've stopped adding. Read the full article on Seeking Alpha지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: CL 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.
배당금 증가: CL 의 배당금 지급은 지난 10 년 동안 증가했습니다.
배당 수익률 vs 시장
| Colgate-Palmolive 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (CL) | 2.3% |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.3% |
| 업계 평균 (Household Products) | 3.1% |
| 분석가 예측 (CL) (최대 3년) | 2.5% |
주목할만한 배당금: CL 의 배당금( 2.34% )은 US 시장에서 배당금 지급자의 하위 25%( 1.42% )보다 높습니다.
고배당: CL 의 배당금( 2.34% )은 US 시장에서 배당금 지급자의 상위 25%( 4.27% )와 비교해 낮습니다.
주주 대상 이익 배당
수익 보장: 현재 지불 비율 ( 80.3% )에서 CL 의 지불은 수입으로 충당됩니다.
주주 현금 배당
현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 45% )로 CL 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 22:24 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Colgate-Palmolive Company는 43명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Christopher Graja | Argus Research Company |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |